Press Releases Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
2.96 ^USD	+1.37%		-1.66%	+23.33%

05:37pm	Capital One Initiates Immutep at Overweight Rating With $10 Price Target	MT
05-15	Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	05-15	AQ
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	05-02	AQ
Immutep Quarterly Activities Report Q3 FY24	04-29	AQ
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	04-18	AQ
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	04-18	PU
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	04-18	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	04-17	AQ
Immutep : Corporate Presentation	03-26	PU
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	03-05	PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	03-05	PU
Immutep Announces First Clinical Data from 90mg Dosing of Efti	03-05	AQ
Immutep Quarterly Activities Report Q2 FY24	01-30	AQ
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer	01-04	AQ
Immutep : Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	12-20	PU
Immutep Receives A$2.6 million R&D Tax Incentive from French Government	12-07	AQ
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial	11-22	AQ
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	11-10	AQ
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	11-09	AQ
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer	11-06	AQ
Immutep : to Participate in November Investor Events	11-01	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Press Releases

Filters